Home
HelpTest Code METF MET (7q31), FISH, Tissue
Reporting Name
MET (7q31), FISH, TsPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Providing prognostic information and guiding treatment primarily for patients with lung, gastric, and colorectal tumors as well as other tumor types
Method Name
Fluorescence In Situ Hybridization (FISH)
Ordering Guidance
This test does not include a pathology consultation. If a pathology consultation is requested, order PATHC / Pathology Consultation, and appropriate testing will be added at the discretion of the pathologist and performed at an additional charge.
Multiple oncology (cancer) gene panels are also available. For more information see Hematology, Oncology, and Hereditary Test Selection Guide
Additional Testing Requirements
Confirmation testing by Microarray testing to resolve atypical fluorescence in situ hybridization results is available, order CMAPT / Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded
Shipping Instructions
Advise Express Mail or equivalent if not on courier service.
Necessary Information
1. A pathology report is required for testing to be performed. If not provided, appropriate testing and/or interpretation may be compromised or delayed. Acceptable pathology reports include working drafts, preliminary pathology, or surgical pathology reports.
2. The following information must be included in the report provided.?
1. Patient name
2. Block number - must be on all blocks, slides, and paperwork?
3. Date of collection
4. Tissue Source
3. A reason for testing must be provided. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
Specimen Required
Submit only 1 of the following specimens:
Preferred
Specimen Type: Tissue block
Collection Instructions: Submit a formalin-fixed, paraffin-embedded tumor tissue block. Blocks prepared with alternative fixation methods will be attempted but are less favorable for successful results by FISH testing; provide fixation method used.
Additional Information:
1. Paraffin-embedded specimens can be from any anatomic location (skin, soft tissue, lymph node, etc).
2. Bone specimens that have been decalcified will be attempted for testing, but the success rate is approximately 50%.
Acceptable?
Specimen Type: Tissue slides
Slides: 1 Hematoxylin and eosin stained and 4 unstained
Collection Instructions: Submit 4 consecutive unstained, positively charged, unbaked slides with 5 micron-thick sections of the tumor tissue and 1 slide stained with hematoxylin and eosin.
Specimen Type
TissueSpecimen Minimum Volume
Slides: 1 Hematoxylin and eosin stained and 2 unstained
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Tissue | Ambient (preferred) | ||
| Refrigerated | |||
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
An interpretive report will be provided.
Interpretation
MET will be clinically interpreted as positive, negative or equivocal.
Establishment of a clear definition of MET amplification has been challenging with the evolution of criteria, as the need to differentiate between true MET amplification and chromosome 7 polysomy has become clear.
For this assay, MET will be reported as amplified (positive) when there is a MET:D7Z1 ratio greater than 2.0 and an average of greater or equal to 5 MET signals/nucleus based on current scientific literature.
Because various other definitions have been proposed, results indicating a greater or equal to 5 MET signals/nucleus with a MET:D7Z1 ratio less than 2.0 will be reported as an equivocal result as this finding likely reflects chromosome 7 polysomy but may represent an unusual mechanism of MET amplification. Similarly, results indicating a MET:D7Z1 ratio greater than 2.0 and less than 5 MET signals/nucleus will be reported as equivocal. Chromosomal microarray studies (TEST: CMAPT) may be considered in these instances to clarify the FISH results.
A result with a MET:D7Z1 ratio less than or equal to 2.0 and an average of less than 5 MET signals/nucleus will be considered negative for amplification of MET.
Patients with 5 or more copies of MET have a poor prognosis.
A negative result does not exclude the presence of a neoplastic disorder.
Day(s) Performed
Monday through Friday
Report Available
7 to 10 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88271x2, 88291-DNA probe, each (first probe set), Interpretation and report
88271x2-DNA probe, each; each additional probe set (if appropriate)
88271x1-DNA probe, each; coverage for sets containing 3 probes (if appropriate)
88271x2-DNA probe, each; coverage for sets containing 4 probes (if appropriate)
88271x3-DNA probe, each; coverage for sets containing 5 probes (if appropriate)
88274 w/modifier 52-Interphase in situ hybridization, <25 cells, each probe set (if appropriate)
88274-Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)Â Â Â Â Â Â Â Â
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| METF | MET (7q31), FISH, Ts | 90926-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 55203 | Result Summary | 50397-9 |
| 55204 | Interpretation | 69965-2 |
| 55206 | Result | 62356-1 |
| CG938 | Reason for Referral | 42349-1 |
| 55207 | Specimen | 31208-2 |
| 55208 | Source | 31208-2 |
| 55209 | Tissue ID | 80398-1 |
| 55210 | Method | 85069-3 |
| 55211 | Additional Information | 48767-8 |
| 55212 | Disclaimer | 62364-5 |
| 55224 | Released By | 18771-6 |
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| _PBCT | Probe, +2 | No, (Bill Only) | No |
| _PADD | Probe, +1 | No, (Bill Only) | No |
| _PB02 | Probe, +2 | No, (Bill Only) | No |
| _PB03 | Probe, +3 | No, (Bill Only) | No |
| _IL25 | Interphases, <25 | No, (Bill Only) | No |
| _I099 | Interphases, 25-99 | No, (Bill Only) | No |
| _I300 | Interphases, >=100 | No, (Bill Only) | No |
Testing Algorithm
This test includes a charge for the probe application, analysis, and professional interpretation of results for one probe set (2 individual fluorescence in situ hybridization probes). No analysis charges will be incurred if an insufficient number of representative cells are available for analysis.
Appropriate ancillary probes may be performed at consultant discretion to render comprehensive assessment. Any additional probes will have the results included within the final report and will be performed at an additional charge.